Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489475 | 0.92 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL801023 | 0.75 | — | — | |
| SCHEMBL801002 | 0.75 | — | — | |
| SCHEMBL767985 | 0.75 | — | — | |
| SCHEMBL13188250 | 0.74 | — | — | |
| SCHEMBL7122074 | 0.74 | — | — | |
| SCHEMBL2903918 | 0.74 | — | — | |
| SCHEMBL13187865 | 0.74 | — | — | |
| SCHEMBL18840134 | 0.72 | — | — | |
| SCHEMBL10120939 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20140309432-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20130309195-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-11-21 | — | — | US | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885 |
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20130309195-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885 |
| US-20140309432-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | HAVCR2, EIF2AK2, HSP90B1 | SMN1; SMN2 4455/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-12037340-B2 | Pentacyclic derivatives as Zika virus inhibitors | ZC3HAV1, ZC3HAV1L, GDI1 | SMN1; SMN2 1957/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.